Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Start-Up Spotlight: NLS Pharma Group
Posted on January 20th, 2017 by Betsy Davis in Pharma R&D
The dedicated scientists at the Switzerland-based NLS Pharma Group are using their collective “brain power” to empower the brain through its many stages of life. Alex Zwyer, CEO of NLS, talks about the therapies that the company is currently working on.
Tell us, in brief, what the company does.
NLS Pharma is a Swiss-based biotech group focusing on the repurposing of established and cost-effective drug/chemical compounds to treat ADHD, sleep disorders, and cognitive impairment.
What does NLS aim to achieve?
The company’s mission is to serve its patients with affordable, safe, and effective therapeutics to safeguard and empower the brain throughout all stages of life. NLS is active in the field of cognitive enhancement and neurosomatic therapies in particular.
Why is the research so important?
These disorders remain largely under-diagnosed and current therapies lack in safety and effectiveness.
Tell us about some of your current work.
NLS-1/NLS-0 (Mazindol) is a CNS drug developed by Sandoz-Wander that blocks the re-uptake of DA and NE. NLS-1, which was approved by the FDA in 1973 for short-term obesity treatment, is a non-amphetaminic stimulant with functional CNS effects similar to AMP and MPH. MZD has shown no potential for abuse, no withdrawal syndrome, and no serious adverse events, even after a long-term exposure. Considering the unique pharmacokinetic’s profile of NLS-1/NLS-0 (10-13 hours), it could be considered as an equally effective but safer alternative to psychostimulants in children and adults with ADHD. Additional USPs may include a full-day therapeutic coverage and inducing quality sleep at bedtime.
On July 11, 2016, the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for NLS-0 (Mazindol) for the treatment of Narcolepsy, and it was granted ODD by the European Commission the previous year.
Here’s what NLS employees are saying about their Phase II proof-of-concept study:
“The first patient in marks an important milestone in the development of a non-amphetaminic stimulant for ADHD.”
– Alex Zwyer, CEO of NLS Pharma Group
“As only a fraction of adults with ADHD are being treated with traditional stimulants, it is clear that alternatives are needed. ADHD can affect numerous aspects of a patient’s life, and the current Phase II study is examining functional outcomes in order to determine the impact of treatment. Depending on the results in adults, this line of research may quickly expand to include younger patients.”
— Dr. Tim Wigal, Lead Investigator
“Clinicians and patients need effective and tolerable non-stimulant alternative medications to treat ADHD. Additionally, at risk populations need safe and non-addictive treatment options. This study creates a unique opportunity for the safe and successful treatment of ADHD in adults.”
— Nelson Handal, MD, Chief Medical Officer of NLS
Are you currently looking for partners or investment?
NLS is always open to discussing partnership strategies. The company is also anticipating a new round of funding soon.
To get in contact with Alex Zwyer, or to follow NLS Pharma Group:
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- Drug Development Insights from the 36th Annual J.P. Morgan Healthcare Conference
- Quantitative Proteomics: A Major Piece in the Precision Medicine Puzzle
- Compound Discovery May Spur Therapies for Autoimmune Conditions
- How Pharma Can Make the Most of Gene Tech CRISPR
- Chemists Concerned About How Their Field is Viewed